Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAYBreak CLL-306 by mid-2026. Nurix maintains a strong cash position of $540.7 million and is expanding bexobrutideg into immunology/inflammation indications with a new tablet formulation targeting 2026 IND submission.

Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion, highlighting the company's broader pipeline expansion strategy.

President Trump signed an executive order imposing 100% tariffs on imported pharmaceuticals, with 13 drug companies already exempt through Most Favored Nation (MFN) pricing agreements. Companies that signed deals and committed to U.S. manufacturing face 0% tariffs through 2029, while non-signatories face the full 100% levy starting July 31. The tariff threat has triggered over $150 billion in domestic manufacturing investments from deal-signing companies.

Keymed Biosciences achieved a major windfall by spinning off its immunotherapy drug into a separate company (Ouro Medicines) that was subsequently acquired by Gilead Sciences for up to $2.175 billion. Keymed stands to receive approximately $320 million in total proceeds while retaining royalty rights. The transaction marks the first complete NewCo cycle exit by a Chinese drugmaker and demonstrates the effectiveness of this globalization strategy for Chinese biotech companies.

The article highlights two dividend-growth stocks that have pulled back due to Middle East tensions despite having no exposure to the conflict. Waste Management (WM) is investing $1.4 billion in AI-powered automation to boost efficiency and free cash flow growth, while Gilead Sciences (GILD) is leveraging AI to accelerate drug development timelines. Both stocks offer attractive entry points with accelerating dividend growth and strong underlying fundamentals.

Galapagos NV has entered into a binding framework agreement with Gilead Sciences to collaborate on developing gamgertamig, a clinical-stage BCMA×CD3 T cell engager for autoimmune diseases. Under the deal, Galapagos will receive 50% of Gilead's $1.675 billion upfront payment for acquiring Ouro Medicines plus 50% of contingent milestone payments. Galapagos will retain $500 million in cash for independent strategic initiatives and is eligible for up to $100 million in additional milestone payments, with tiered royalties of 20-23% on net sales.

The global bile duct cancer market is projected to expand from $2.59 billion in 2025 to $3.89 billion by 2030, growing at an 8.4% CAGR. Growth is driven by advancements in early diagnostics, increased adoption of immunotherapy and targeted therapies, AI-assisted diagnostics, and rising prevalence of liver diseases. Major pharmaceutical companies are introducing innovative treatments and forming strategic partnerships to enhance patient outcomes.

SK pharmteco announced it will host a one-day scientific symposium on April 8th in Cambridge, Massachusetts focused on continuous manufacturing, advanced processing, and scalable technologies in pharmaceutical production. The event will feature keynote speakers and expert panels from leading organizations including Gilead, Antheia, Eli Lilly, and Amgen to discuss the future of pharmaceutical manufacturing.

Gilead Sciences agreed to acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments to strengthen its inflammation and autoimmune disease pipeline. The clinical-stage drug OM336, a bispecific T cell engager, will be co-developed with Galapagos NV, which will fund 50% of upfront costs and development expenses through registrational studies. Gilead retains global commercialization rights and will pay Galapagos 20-23% royalties on net sales.

Galapagos and Gilead are in advanced discussions for a strategic partnership following Gilead's acquisition of Ouro Medicines. Under the proposed collaboration, Galapagos would co-develop OM336 (gamgertamig), a BCMA-targeted T-cell engager for autoimmune diseases, with improved financial terms including 50% cost-sharing for registration studies and 20-23% royalties on net sales. The deal would also free up €500 million of Galapagos' capital for strategic flexibility.

Galapagos and Gilead are in advanced partnership discussions following Gilead's acquisition of Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments. Under the proposed collaboration, Galapagos would pay 50% of acquisition costs, absorb Ouro's operating assets, and lead development through registrational studies, while Gilead retains commercialization rights and pays 20-23% royalties. The partnership would free up $500 million of Galapagos' cash for independent strategic initiatives.